United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 6

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 6 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderiRhythm Tech · 49

Strongest available pathiRhythm Tech · +108.9%

Widest latest marginResMed · 27.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1IRTC · Nasdaq

iRhythm Tech

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2006San Francisco$4.03B market cap

View full Companies Radar profile

49Cautious

Snapshot price$122.3as of page date

Monthly-close return+108.9%five-year window

FY2025 revenue$0.75BiRhythm Holdings, Inc.

Net margin-6.0%FY2025

P/E snapshot100.8xone ratio, not a verdict

Prism attention11.5%share across these five

Filing track recordRevenue, USD billions

+131.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 23.3%

52-week position19% through range

$100.8$212.0

News mentions1.2K

Community mentions1partial coverage

U.S.-scope patents208

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 3 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ANGO · Nasdaq

AngioDynamics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1988Latham, New York$655.5M market cap

View full Companies Radar profile

45Cautious

Snapshot price$15.86as of page date

Monthly-close return-38.9%five-year window

FY2025 revenue$0.29BANGIODYNAMICS INC

Net margin-11.6%FY2025

P/E snapshot-352.4xone ratio, not a verdict

Prism attention18.5%share across these five

Filing track recordRevenue, USD billions

+0.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 0.1%

52-week position94% through range

$9.39$16.29

News mentions1.9K

Community mentions0partial coverage

U.S.-scope patents621

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal61/100
Management stability90/100
Market position21/100
Capital-event signal20/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 10 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3XAIR · NASDAQ

Beyond Air

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2011Garden City, New York$3.6M market cap

View full Companies Radar profile

45Cautious

Snapshot price$3.66as of page date

Monthly-close return-99.9%five-year window

FY2025 revenue$0.00BBeyond Air, Inc.

Net margin-1258.4%FY2025

P/E snapshot0.0xone ratio, not a verdict

Prism attention4.5%share across these five

Filing track recordRevenue, USD billions

+166.5%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 27.8%

52-week position0% through range

$3.60$95.60

News mentions463

Community mentions0partial coverage

U.S.-scope patents75

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position0/100
Capital-event signal56/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4WST · NYSE

West Pharmaceutical Services

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1923EXTON$23.83B market cap

View full Companies Radar profile

45Cautious

Snapshot price$338.6as of page date

Monthly-close return-20.2%five-year window

FY2025 revenue$3.07BWEST PHARMACEUTICAL SERVICES INC

Net margin16.1%FY2025

P/E snapshot43.4xone ratio, not a verdict

Prism attention23.3%share across these five

Filing track recordRevenue, USD billions

+8.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%

52-week position71% through range

$223.8$386.0

News mentions2.4K

Community mentions12partial coverage

U.S.-scope patents459

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal15/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RMD · NYSE

ResMed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2010San Diego, California$33.37B market cap

View full Companies Radar profile

44Cautious

Snapshot price$231.4as of page date

Monthly-close return-12.2%five-year window

FY2025 revenue$5.15BRESMED INC

Net margin27.2%FY2025

P/E snapshot22.2xone ratio, not a verdict

Prism attention42.2%share across these five

Filing track recordRevenue, USD billions

+61.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.6%

52-week position49% through range

$180.3$284.9

News mentions4.3K

Community mentions22.9Kpartial coverage

U.S.-scope patents702

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position16/100
Capital-event signal5/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 25 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

iRhythm Tech

+108.9%

ResMed

-12.2%

West Pharmaceutical Services

-20.2%

AngioDynamics

-38.9%

Beyond Air

-99.9%

Latest revenue

USD billions, official filing scope shown on each company card.

ResMed

$5.15B

West Pharmaceutical Services

$3.07B

iRhythm Tech

$0.75B

AngioDynamics

$0.29B

Beyond Air

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

ResMed

27.2%

West Pharmaceutical Services

16.1%

iRhythm Tech

-6.0%

AngioDynamics

-11.6%

Beyond Air

-1258.4%

Prism news attention

Normalized share across these five names; attention is not quality.

ResMed

42.2%

West Pharmaceutical Services

23.3%

AngioDynamics

18.5%

iRhythm Tech

11.5%

Beyond Air

4.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

ResMed leads the conversation

It holds 42.2% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $5.15B.

Price path

iRhythm Tech leads the available price paths

Its monthly-close return is +108.9% for the five-year window. At the other end, Beyond Air is -99.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

ResMed has the widest latest margin

Its FY2025 net margin is 27.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

AngioDynamics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -352.4x while its five-year window price return is -38.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · IRTC

iRhythm Tech

1,172available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+29.1%226 latest 12m vs 175 prior 12m

Machine-classified coverage tone

92.5% positive-0.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smartwatch health monitor 48wearable ecg 39remote ecg monitoring 28remote patient monitor 27telehealth monitor 22stock price 18remote vital signs monitor 16wearable biotech 16

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-13–2026-06-18 · trend and themes shown through 2026-06

Areas of research · ANGO

AngioDynamics

1,892available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Macro demand & rates

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-29.5%256 latest 12m vs 363 prior 12m

Machine-classified coverage tone

91.2% positive+2.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 22vascetomy prostate cancer 15prostatic intraepithelial neoplasia 14earnings report 13diet prostate cancer 13age prostate cancer 11financial report 10market momentum 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-30 · trend and themes shown through 2026-06

Areas of research · WST

West Pharmaceutical Services

2,382available Prism news records

Prism top themes

Price action & investor response

201

Earnings & financial performance

119

Legal, arbitration & regulatory

Macro demand & rates

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+110.1%603 latest 12m vs 287 prior 12m

Machine-classified coverage tone

91.6% positive+6.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smart packaging 69anti-counterfeiting packaging 56temperature-sensitive packaging 48stock price 39drug distribution 33stock performance 32investment deal 21earnings report 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-19 · trend and themes shown through 2026-06

Areas of research · RMD

ResMed

4,317available Prism news records

Prism top themes

Price action & investor response

240

Earnings & financial performance

155

Macro demand & rates

102

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+12.0%571 latest 12m vs 510 prior 12m

Machine-classified coverage tone

83.6% positive-1.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 59cpap machine 33stock price 30earnings report 27cpap mask 23investment deal 23quarterly results 22market rally 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-31–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

RMD

ResMed

22,949 mentions

Products, pricing and logistics

20,932

Stock and valuation

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 22,949 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

IRTC

iRhythm Tech

through 2026-04-09

Earnings releases 24Lawsuits 15Leadership changes 5Business contracts 1Company announcements 1

2026-04-09
Lawsuits
According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real‑time monitor intended for high‑risk patients.
2026-03-25
Earnings releases
The gross profit of Irhythm Technologies with headquarters in the United States amounted to *************** U.S. dollars in 2025.
2025-07-07
Leadership changes
On July 7, 2025, iRhythm Technologies announced the retirement of long-serving board members Mark Rubash and Ralph Snyderman, M.D., and the appointment of Karen McGinnis and Kevin O'Boyle to the board of directors.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ANGO

AngioDynamics

through 2026-04-08

Earnings releases 24Asset acquisitions 5M&A 5Leadership changes 2Lawsuits 1

2026-04-08
Earnings releases
HC Wainwright also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.03) EPS.
2025-02-14
M&A
AngioDynamics reported that the U.S. Bankruptcy Court ... has granted an order approving AngioDynamics' purchase of certain U.S. assets of Diomed Holdings and its subsidiary, Diomed ...
2025-02-14
Listing / IPO
AngioDynamics (Queensbury, New York) reported that it is offering 2.4 million shares of its common stock at a public offering price of $24.07 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

XAIR

Beyond Air

through 2026-02-13

Earnings releases 9Company announcements 5Leadership changes 2Business contracts 1Regulatory 1

2026-02-13
Earnings releases
Revenues for the fiscal quarter ended December 31, 2025 increased 105% to $2.2 million , compared with $1.1 million for the fiscal quarter ended December 31, 2024.
2025-12-30
Leadership changes
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), ... today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026.
2025-11-26
Regulatory
Beyond Air has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WST

West Pharmaceutical Services

through 2026-04-23

Earnings releases 42Leadership changes 8Lawsuits 3Company announcements 2Asset acquisitions 1

2026-04-23
Earnings releases
West Pharmaceutical Services updated its Q2 2026 guidance to 2.050-2.120 EPS.
2026-03-31
Company announcements
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services.
2026-03-09
Leadership changes
West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RMD

ResMed

through 2026-02-03

Earnings releases 53Leadership changes 14Company announcements 7M&A 5Business contracts 1

2026-02-03
Earnings releases
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$1.45 billion and a net profit of A$399.08 million.
2025-12-01
Leadership changes
Karen Drexler has served as a ResMed director since November 2017
2025-05-01
M&A
Resmed (NYSE: RMD) + announced today that it acquired VirtuOx, a leading independent diagnostic testing facility (IDTF).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 26–33. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

iRhythm Tech leads the readiness ranking

Its Prism readiness score is 49/100, the highest in this five-company comparison.

Open iRhythm Tech in Companies Radar

Scale and margin leadership sit with ResMed and ResMed

ResMed has the largest displayed latest revenue at $5.15B; ResMed has the widest displayed latest margin at 27.2%.

Open ResMed in Companies Radar

Comparisons

Strongest versus weakest available price path

iRhythm Tech is +108.9% for its five-year window; Beyond Air is -99.9% for its five-year window.

Open iRhythm Tech in Companies Radar Open Beyond Air in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $5.15B for ResMed to $0.00B for Beyond Air. Entity and filing-period labels remain visible on the company cards.

Open ResMed in Companies Radar Open Beyond Air in Companies Radar

Anomalies

ResMed has the widest attention-readiness rank gap

It ranks #1 by measured news attention (42.2%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open ResMed in Companies Radar

Beyond Air shows a price-operating divergence to inspect

Its displayed filing-revenue change is +166.5% while its available monthly-close return is -99.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Beyond Air in Companies Radar

Explanations

Attention measures coverage volume, not quality

ResMed's 42.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open ResMed in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open iRhythm Tech's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open iRhythm Tech in Companies Radar

Stress-test the largest divergence before forming a view

Compare Beyond Air's profile with iRhythm Tech's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Beyond Air in Companies Radar Open iRhythm Tech in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.